NVX-CoV2373 COVID vaccine safe and effective in preventing COVID-19 in adolescent

Research reports the results of a phase 3 clinical trial evaluating the safety, immunogenicity, and efficacy of the NVX-CoV2373 vaccine in adolescents aged 12 to 17 years. The study found that the vaccine was safe, immunogenic, and efficacious in preventing COVID-19, including the Delta variant, in adolescents.

Related Keywords

United States ,Pooja Toshniwal Paharia ,Pooja Toshniwal Pahariaapr , ,Pooja Toshniwal ,Randomized Clinical ,Image Credit ,Coronavirus Disease Covid 19 ,Vaccine ,Adolescents ,Ntibody ,Children ,Clinical Trial ,Coronavirus ,Efficacy ,Nzyme ,Global Health ,Mental Health ,Ortality ,Micron ,Placebo ,Protein ,Espiratory ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,